FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808020132> ?p ?o ?g. }

• W2808020132 endingPage "2575" @default.
• W2808020132 startingPage "2567" @default.
• W2808020132 abstract "Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third‐line treatment for pretreated metastatic colorectal cancer (mCRC) patients harboring wild‐type KRAS exon 2. Objective response rate (ORR) was used as primary endpoint based on an expected proportion of 0.23 with confidence width of 0.298 (95% CI, 0.105‐0.403), which showed 35 to be the minimal participant number. Forty patients, refractory to first‐ and second‐line chemotherapy containing irinotecan, oxaliplatin, and fluoropyrimidine, were enrolled. ORR and disease control rate were 25.0% (95% CI : 11.5‐38.4) and 72.5% (95% CI : 56.8‐86.4), respectively. Median progression‐free survival (PFS), overall survival (OS), and number of courses were 5.70 months (95% CI : 2.7‐7.9), 15.1 months (95% CI : 11.8‐19.0), and 10.5 (range: 3.0‐31.0), respectively. Grade 3 adverse events were skin toxicity (12.5%), diarrhea (10.0%), neutropenia (5.0%), febrile neutropenia (5.0%), nausea (5.0%), anorexia (5.0%), and fatigue (2.5%). C max mean was 723.2 μg/mL after first dose. High area under the curve ( AUC ) last variance was associated with t 1/2 range of 131.2‐1209.6 hours (median, 174.4 hours). Early tumor shrinkage (ETS) and median depth of response were 25.0% and 13.0%, respectively. Mutation frequencies in KRAS exon 3 or 4, NRAS , BRAF , and PIK 3 CA were 5.5%, 2.7%, 8.3%, and 5.5%, respectively. Multivariate Cox regression analysis assessed whether any gene mutations and ETS are predictors for PFS, and whether performance status, synchronous metastasis, and ETS are predictors for OS. Importantly, the data provide guidance for a biweekly cetuximab plus irinotecan regimen in mCRC patients." @default.
• W2808020132 created "2018-06-21" @default.
• W2808020132 creator A5014800720 @default.
• W2808020132 creator A5039514890 @default.
• W2808020132 creator A5047876211 @default.
• W2808020132 creator A5064316490 @default.
• W2808020132 creator A5064875409 @default.
• W2808020132 creator A5066658797 @default.
• W2808020132 creator A5069216523 @default.
• W2808020132 creator A5070643359 @default.
• W2808020132 creator A5077085235 @default.
• W2808020132 creator A5078320729 @default.
• W2808020132 creator A5083889178 @default.
• W2808020132 creator A5091623593 @default.
• W2808020132 creator A5091701897 @default.
• W2808020132 date "2018-07-13" @default.
• W2808020132 modified "2023-10-16" @default.
• W2808020132 title "Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer" @default.
• W2808020132 cites W1933451634 @default.
• W2808020132 cites W2015132197 @default.
• W2808020132 cites W2021585972 @default.
• W2808020132 cites W2023807845 @default.
• W2808020132 cites W2060189595 @default.
• W2808020132 cites W2068125497 @default.
• W2808020132 cites W2085633477 @default.
• W2808020132 cites W2104804192 @default.
• W2808020132 cites W2112570485 @default.
• W2808020132 cites W2133045939 @default.
• W2808020132 cites W2134519717 @default.
• W2808020132 cites W2137759849 @default.
• W2808020132 cites W2142350279 @default.
• W2808020132 cites W2142564546 @default.
• W2808020132 cites W2165385913 @default.
• W2808020132 cites W2166400927 @default.
• W2808020132 cites W2409420104 @default.
• W2808020132 cites W2465966893 @default.
• W2808020132 cites W2531319683 @default.
• W2808020132 cites W2589677705 @default.
• W2808020132 cites W2609927476 @default.
• W2808020132 cites W4385789423 @default.
• W2808020132 doi "https://doi.org/10.1111/cas.13698" @default.
• W2808020132 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6113428" @default.
• W2808020132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29908105" @default.
• W2808020132 hasPublicationYear "2018" @default.
• W2808020132 type Work @default.
• W2808020132 sameAs 2808020132 @default.
• W2808020132 citedByCount "4" @default.
• W2808020132 countsByYear W28080201322020 @default.
• W2808020132 countsByYear W28080201322021 @default.
• W2808020132 countsByYear W28080201322022 @default.
• W2808020132 countsByYear W28080201322023 @default.
• W2808020132 crossrefType "journal-article" @default.
• W2808020132 hasAuthorship W2808020132A5014800720 @default.
• W2808020132 hasAuthorship W2808020132A5039514890 @default.
• W2808020132 hasAuthorship W2808020132A5047876211 @default.
• W2808020132 hasAuthorship W2808020132A5064316490 @default.
• W2808020132 hasAuthorship W2808020132A5064875409 @default.
• W2808020132 hasAuthorship W2808020132A5066658797 @default.
• W2808020132 hasAuthorship W2808020132A5069216523 @default.
• W2808020132 hasAuthorship W2808020132A5070643359 @default.
• W2808020132 hasAuthorship W2808020132A5077085235 @default.
• W2808020132 hasAuthorship W2808020132A5078320729 @default.
• W2808020132 hasAuthorship W2808020132A5083889178 @default.
• W2808020132 hasAuthorship W2808020132A5091623593 @default.
• W2808020132 hasAuthorship W2808020132A5091701897 @default.
• W2808020132 hasBestOaLocation W28080201321 @default.
• W2808020132 hasConcept C121608353 @default.
• W2808020132 hasConcept C126322002 @default.
• W2808020132 hasConcept C141071460 @default.
• W2808020132 hasConcept C143998085 @default.
• W2808020132 hasConcept C197934379 @default.
• W2808020132 hasConcept C203092338 @default.
• W2808020132 hasConcept C2776694085 @default.
• W2808020132 hasConcept C2777063308 @default.
• W2808020132 hasConcept C2778375690 @default.
• W2808020132 hasConcept C2779998722 @default.
• W2808020132 hasConcept C2780259306 @default.
• W2808020132 hasConcept C2781187634 @default.
• W2808020132 hasConcept C31760486 @default.
• W2808020132 hasConcept C526805850 @default.
• W2808020132 hasConcept C535046627 @default.
• W2808020132 hasConcept C71924100 @default.
• W2808020132 hasConcept C90924648 @default.
• W2808020132 hasConceptScore W2808020132C121608353 @default.
• W2808020132 hasConceptScore W2808020132C126322002 @default.
• W2808020132 hasConceptScore W2808020132C141071460 @default.
• W2808020132 hasConceptScore W2808020132C143998085 @default.
• W2808020132 hasConceptScore W2808020132C197934379 @default.
• W2808020132 hasConceptScore W2808020132C203092338 @default.
• W2808020132 hasConceptScore W2808020132C2776694085 @default.
• W2808020132 hasConceptScore W2808020132C2777063308 @default.
• W2808020132 hasConceptScore W2808020132C2778375690 @default.
• W2808020132 hasConceptScore W2808020132C2779998722 @default.
• W2808020132 hasConceptScore W2808020132C2780259306 @default.
• W2808020132 hasConceptScore W2808020132C2781187634 @default.
• W2808020132 hasConceptScore W2808020132C31760486 @default.
• W2808020132 hasConceptScore W2808020132C526805850 @default.
• W2808020132 hasConceptScore W2808020132C535046627 @default.

• next